Neovacs SA
ALNEV
Company Profile
Business description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Contact
3-5, Impasse Reille
Paris75014
FRAT: +33 153109300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.90 | 5.10 | 0.06% |
| CAC 40 | 7,615.97 | 0.02 | -0.00% |
| DAX 40 | 23,587.61 | 53.97 | -0.23% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,762.61 | 3.62 | 0.04% |
| HKSE | 24,474.67 | 297.60 | 1.23% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,942.07 | 151.51 | 0.39% |
| NZX 50 Index | 12,460.96 | 6.52 | -0.05% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.20 | 3.70 | 0.04% |
| SSE Composite Index | 3,455.97 | 35.41 | 1.04% |